Cyclacel Pharmaceuticals, Inc. (CYCCP)
Chart Events
Performance Outlook
| Previous Close | 6.75 |
| Open | 6.77 |
| Bid | 6.10 x 1000 |
| Ask | 7.46 x 1800 |
| Day's Range | 6.77 - 6.77 |
| 52 Week Range | 5.17 - 11.17 |
| Volume | |
| Avg. Volume | 114 |
| Market Cap | 12.873M |
| Beta (5Y Monthly) | 1.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.05 |
| Earnings Date | May 12, 2020 |
| Forward Dividend & Yield | 0.60 (8.94%) |
| Ex-Dividend Date | Oct 14, 2021 |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CYCCP
Related Research
- Cyclacel Pharmaceuticals, Inc.Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.RatingFair ValueEconomic Moat2 days agoMorningstar
- GlobeNewswire
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors
BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors. Dr. Ferguson was elected by and will represent the 6% Convertible Exchangeable Preferred stockholders. "We are very pleased to welcome Ken to our Board of Directors,” said Ch
- Insider Monkey
10 Popular Penny Stocks on Robinhood
In this article, we discuss the 10 popular penny stocks on Robinhood. If you want to skip our analysis of these stocks, go directly to the 5 Popular Penny Stocks on Robinhood. According to the letter acquired by CNBC from Citadel Securities’ Institutional Equity Derivatives team, stocks selling below $1 per share recorded an average […]
- GlobeNewswire
Cyclacel Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC140 for Treatment of Advanced Solid Tumors and Lymphomas - - Publication Confirming Fadraciclib Suppresses MCL1 and Synergistic Activity with Venetoclax in CLL - - Cash Runway through Mid-2023 - - Conference Call Scheduled for May 11, 2022 at 4:30 pm EDT - BERKELEY HEIGHTS, N.J., May 11, 2022 (GLOBE NEWSWIR
